Incidence and Consequence of Nontarget Embolization Following Bland Hepatic Arterial Embolization

2019 ◽  
Vol 42 (8) ◽  
pp. 1135-1141 ◽  
Author(s):  
Brandon J. Newgard ◽  
George I. Getrajdman ◽  
Joseph P. Erinjeri ◽  
Anne M. Covey ◽  
Lynn A. Brody ◽  
...  
1993 ◽  
Vol 29 (5) ◽  
pp. 1020 ◽  
Author(s):  
Tae Hoon Kim ◽  
Yup Yoon ◽  
Jae Hoon Lim ◽  
Young Tae Ko ◽  
Dong Ho Lee

2013 ◽  
Vol 32 (9) ◽  
pp. 954-958
Author(s):  
Dong-juan XING ◽  
Wei-hua SONG ◽  
Shao-juan GONG ◽  
Ai-min XU ◽  
Xiao-wei LI ◽  
...  

2011 ◽  
Vol 70 (5) ◽  
pp. 1032-1037 ◽  
Author(s):  
Christian Letoublon ◽  
Irene Morra ◽  
Yao Chen ◽  
Valerie Monnin ◽  
David Voirin ◽  
...  

1988 ◽  
Vol 67 (12) ◽  
pp. 1142???1148 ◽  
Author(s):  
H. Ahlman ◽  
L. ??hlund ◽  
A. Dahlstr??m ◽  
J. Martner ◽  
O. Stenqvist ◽  
...  

2018 ◽  
Vol 31 (05) ◽  
pp. 301-308 ◽  
Author(s):  
Raphael Byrne ◽  
Rodney Pommier

AbstractNeuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.


Author(s):  
Masato Fujita ◽  
Tetsuya Katsumori ◽  
Osamu Satoh ◽  
Takeshi Takahashi ◽  
Syoichi Akimoto ◽  
...  

Kanzo ◽  
1991 ◽  
Vol 32 (7) ◽  
pp. 700-707 ◽  
Author(s):  
Akihiko OHKUSA ◽  
Hiroyasu YOSHIOKA ◽  
Yukihiko ONO ◽  
Tatsumasa OKAFUJI ◽  
Osamu ISHIDA

Sign in / Sign up

Export Citation Format

Share Document